| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $53.8M | +52.4% |
| SG&A Expense | $18.7M | +26.2% |
| Operating Income | -$56.1M | -11.9% |
| Net Income | -$53.8M | -7.7% |
| EPS (Basic) | -$1.86 | +83.0% |
| EPS (Diluted) | -$1.86 | +83.0% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $129.3M | -17.9% |
| Current Assets | $140.2M | -13.0% |
| Total Assets | $160.2M | -10.6% |
| Current Liabilities | $24.0M | +102.0% |
| Total Liabilities | $37.9M | +43.2% |
| Stockholders' Equity | $122.3M | -19.9% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$40.6M | +5.3% |
| Capital Expenditures | $3.6M | +625.1% |
| Investing Cash Flow | -$3.6M | -625.1% |
| Financing Cash Flow | $15.9M | -85.5% |
| Free Cash Flow | -$44.2M | -1.9% |